

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6171589

<b>SUBMISSION TYPE:</b>	CORRECTIVE ASSIGNMENT						
<b>NATURE OF CONVEYANCE:</b>	Corrective Assignment to correct the ASSIGNEE NAME (RECEIVING PARTY DATA) previously recorded on Reel 051449 Frame 0925. Assignor(s) hereby confirms the ASSIGNMENT.						
<b>CONVEYING PARTY DATA</b>							
<table border="1"><thead><tr><th>Name</th><th>Execution Date</th></tr></thead><tbody><tr><td>ALFREDO C. CASTRO</td><td>04/27/2018</td></tr><tr><td>CATHERINE ANNE EVANS</td><td>05/02/2018</td></tr></tbody></table>	Name	Execution Date	ALFREDO C. CASTRO	04/27/2018	CATHERINE ANNE EVANS	05/02/2018	
Name	Execution Date						
ALFREDO C. CASTRO	04/27/2018						
CATHERINE ANNE EVANS	05/02/2018						
<b>RECEIVING PARTY DATA</b>							
<b>Name:</b>	KYN THERAPEUTICS INC.						
<b>Street Address:</b>	400 TECHNOLOGY SQUARE, 10TH FLOOR						
<b>City:</b>	CAMBRIDGE						
<b>State/Country:</b>	MASSACHUSETTS						
<b>Postal Code:</b>	02139						
<b>PROPERTY NUMBERS Total: 1</b>							
<table border="1"><thead><tr><th>Property Type</th><th>Number</th></tr></thead><tbody><tr><td>Application Number:</td><td>16668070</td></tr></tbody></table>	Property Type	Number	Application Number:	16668070			
Property Type	Number						
Application Number:	16668070						
<b>CORRESPONDENCE DATA</b>							
<b>Fax Number:</b>	(617)426-6567						
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>							
<b>Phone:</b>	6177287100						
<b>Email:</b>	BOSPatents@dechert.com						
<b>Correspondent Name:</b>	DECHERT LLP						
<b>Address Line 1:</b>	ONE INTERNATIONAL PLACE, 40TH FLOOR						
<b>Address Line 2:</b>	100 OLIVER STREET						
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02110-2605						
<b>ATTORNEY DOCKET NUMBER:</b>	396661-001USD1 (170588)						
<b>NAME OF SUBMITTER:</b>	GANG WANG						
<b>SIGNATURE:</b>	/Gang Wang/						
<b>DATE SIGNED:</b>	06/25/2020						
<b>Total Attachments: 5</b>							
source=Kyn_170588_Assignment_Corrected#page1.tif							
source=Kyn_170588_Assignment_Corrected#page2.tif							

source=Kyn\_170588\_Assignment\_Corrected#page3.tif

source=Kyn\_170588\_Assignment\_Corrected#page4.tif

source=Kyn\_170588\_Assignment\_Corrected#page5.tif

**PATENT**

**REEL: 053038 FRAME: 0243**



United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)*Electronic Patent Assignment System***Confirmation Receipt**

Your assignment has been received by the USPTO.  
The coversheet of the assignment is displayed below:

**PATENT ASSIGNMENT COVER SHEET**

Electronic Version v1.1

Stylesheet Version v1.2

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT												
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT												
<b>CONVEYING PARTY DATA</b>													
<table border="1"><thead><tr><th>Name</th><th>Execution Date</th></tr></thead><tbody><tr><td>ALFREDO C. CASTRO</td><td>04/27/2018</td></tr><tr><td>CATHERINE ANNE EVANS</td><td>05/02/2018</td></tr></tbody></table>	Name	Execution Date	ALFREDO C. CASTRO	04/27/2018	CATHERINE ANNE EVANS	05/02/2018							
Name	Execution Date												
ALFREDO C. CASTRO	04/27/2018												
CATHERINE ANNE EVANS	05/02/2018												
<b>RECEIVING PARTY DATA</b>													
<table border="1"><tr><td><b>Name:</b></td><td>[[ KYN THERAPEUTICS ]] KYN THERAPEUTICS INC.</td></tr><tr><td><b>Street Address:</b></td><td>400 TECHNOLOGY SQUARE</td></tr><tr><td><b>Internal Address:</b></td><td>10TH FLOOR</td></tr><tr><td><b>City:</b></td><td>CAMBRIDGE</td></tr><tr><td><b>State/Country:</b></td><td>MASSACHUSETTS</td></tr><tr><td><b>Postal Code:</b></td><td>02139</td></tr></table>		<b>Name:</b>	[[ KYN THERAPEUTICS ]] KYN THERAPEUTICS INC.	<b>Street Address:</b>	400 TECHNOLOGY SQUARE	<b>Internal Address:</b>	10TH FLOOR	<b>City:</b>	CAMBRIDGE	<b>State/Country:</b>	MASSACHUSETTS	<b>Postal Code:</b>	02139
<b>Name:</b>	[[ KYN THERAPEUTICS ]] KYN THERAPEUTICS INC.												
<b>Street Address:</b>	400 TECHNOLOGY SQUARE												
<b>Internal Address:</b>	10TH FLOOR												
<b>City:</b>	CAMBRIDGE												
<b>State/Country:</b>	MASSACHUSETTS												
<b>Postal Code:</b>	02139												
<b>PROPERTY NUMBERS Total: 1</b>													
<table border="1"><thead><tr><th>Property Type</th><th>Number</th></tr></thead><tbody><tr><td><b>Application Number:</b></td><td>16668070</td></tr></tbody></table>	Property Type	Number	<b>Application Number:</b>	16668070									
Property Type	Number												
<b>Application Number:</b>	16668070												

**PATENT**

**CORRESPONDENCE DATA**

**Fax Number:** (617)426-6567   
**Phone:** 617-728-7100   
**Email:** BOSPatents@dechert.com

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Correspondent Name:** DECHERT LLP  
**Address Line 1:** ONE INTERNATIONAL PLACE, 40TH FLOOR  
**Address Line 2:** 100 OLIVER STREET  
**Address Line 4:** BOSTON, MASSACHUSETTS 02110-2605

**ATTORNEY DOCKET  
NUMBER:**

396661-001USC1 (170588)

**NAME OF SUBMITTER:**

GANG WANG

**Signature:**

/Gang Wang/

**Date:**

01/08/2020

**Total Attachments: 3**

source=2020-01-06\_Kyn\_170588\_Parent\_Assignment#page1.tif  
source=2020-01-06\_Kyn\_170588\_Parent\_Assignment#page2.tif  
source=2020-01-06\_Kyn\_170588\_Parent\_Assignment#page3.tif

**RECEIPT INFORMATION**

**EPAS ID:** PAT5899964  
**Receipt Date:** 01/08/2020

[Return to home page](#)

| [HOME](#) | [INDEX](#) | [SEARCH](#) | [BUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)

**PATENT**

**COMBINED DECLARATION (37 CFR § 1.63) AND ASSIGNMENT (DUAL PURPOSE)  
FOR UTILITY OR DESIGN PATENT APPLICATION USING AN APPLICATION DATA SHEET**

**DECLARATION:**

The within-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both.

**ASSIGNMENT:**

WHEREAS, we, the undersigned,

**Alfredo C. CASTRO**, resident of 14 Kelly Drive, Woburn, Massachusetts 01801, USA;

**Catherine Anne EVANS**, resident of 83 Jaques Street, Somerville, Massachusetts 02145, USA;

are inventors of the invention described and claimed in "INDOLE AHR INHIBITORS AND USES THEREOF" and hereby execute an application for a patent of the United States, having Application No. 15/958,586, filing date of April 20, 2018, and

are also aware of the following priority applications:

62/488,476, filing date of April 21, 2017;

62/592,542, filing date of November 30, 2017;

62/658,454, filing date of April 16, 2018;

KYN THERAPEUTICS INC. GW 06/25/2020

WHEREAS, ~~KYN THERAPEUTICS~~ (hereinafter termed "Assignee"), having a place of business at 400 Technology Square, 10<sup>th</sup> Floor, Cambridge, Massachusetts 02139, USA, desires to acquire the entire right, title and interest in and to said application and the invention disclosed therein, and in and to all embodiments of the invention, heretofore conceived, made or discovered by us (all collectively hereinafter termed "said invention"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter termed "patents") thereon granted in the United States and foreign countries.

NOW, THEREFORE, in consideration of good and valuable consideration, receipt and sufficiency of which is acknowledged by us to have been received in full from said Assignee:

1. We do hereby sell, assign, transfer and convey unto said Assignee, and/or confirm prior assignment, transfer, or conveyance unto said Assignee, the entire right, title and interest (a) in and to said application and said invention; (b) in and to all rights to apply for foreign patents on said invention pursuant to the International Convention for the Protection of Industrial Property or otherwise; (c) in and to any and all applications filed and any and all patents granted on said invention in the United States or any foreign country, including each and every application filed and each and every patent granted on any application which is a division, substitution, or continuation of any of said applications; and (d) in and to each and every reissue or extensions of any of said patents.

2. We hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right title and interest herein conveyed in the United States and foreign countries. Such cooperation by us shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said invention; (d) for filing and prosecuting applications for reissuance of any said patents; (e) for interference or other priority proceedings involving said invention; and (f) for legal proceedings involving said invention and any applications therefor and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by us in providing such cooperation shall be paid for by said Assignee.


3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon us, our respective heirs, legal representatives and assigns.

4. We hereby warrant and represent that we have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

IN WITNESS WHEREOF, we have executed and delivered this instrument to said Assignee.

KYN THERAPEUTICS INC. GW 06/25/2020






~~KYN THERAPEUTICS~~ ("Assignee")

By: \_\_\_\_\_

Name: Mark Manfredi

Title: President and CEO

Date: May 18, 2018

By:  Alfredo C. CASTRO	By:  Catherine Anne EVANS
Date: 4/27/2018	Date: 2 May 2018
WITNESSES: Signature: 	WITNESSES: Signature: 
Signature: 	Signature: 